Colorectal cancer is the third-most-common cancer globally and is associated with a five-year overall survival of 65.1%. Current treatment for metastatic colorectal cancer is dominated by…
The Parkinson’s disease (PD) market is in the midst of transformation: the first new levodopa formulation (Rytary) in over a decade launched in 2015 with more on the horizon (e.g., ND-0612, AP-…
The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23…
The schizophrenia market is highly crowded given the presence of numerous antipsychotic therapies including the continued genericization of key oral therapies, the availability of newer oral…
The mature rheumatoid arthritis (RA) market boasts ten different biologics representing several distinct drug classes, including blockbuster tumor necrosis factor alpha (TNF-α) inhibitors Enbrel (…
MARKET OUTLOOK The human immunodeficiency virus (HIV) therapy market is dynamic and growing as many effective antiretroviral therapies (ARTs), such as Gilead’s Biktarvy, continue to launch,…
MARKET OUTLOOK The human immunodeficiency virus (HIV) therapy market is dynamic and growing as many effective antiretroviral therapies (ARTs), such as Gilead’s Biktarvy, continue to launch,…
MARKET OUTLOOK Sickle cell disease (SCD) is a rare genetic blood disorder characterized by a polymerization of hemoglobin in red blood cells (RBCs) that causes the cells to become distorted into a…
Epilepsy, which afflicts approximately 4.7 million people in the G7 according to DRGepidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s…
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant public health and financial burden. The availability of non-vitamin K…
The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair/Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva),…
Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disease characterized by progressive chorea, dystonia, and cognitive decline. Current treatment is entirely focused on…
MARKET OUTLOOK Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. Significant…
MARKET OUTLOOK Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. Significant…
MARKET OUTLOOK Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. Significant…